Calibre One Enhances Biopharmaceutical Search with Jed Donnelly; Impact on Redhill Biopharma?
- Calibre One appointed Jed Donnelly as Partner to enhance biopharmaceutical executive search capabilities.
- Donnelly brings over 20 years of experience in biopharmaceutical and life sciences executive placements.
- His expertise aligns with Calibre One’s mission to support and advance the healthcare sector.
Calibre One Strengthens Biopharmaceutical Executive Search with New Partner Appointment
Calibre One, a leading global executive search firm, enhances its expertise in the biopharmaceutical sector with the appointment of Jed Donnelly as Partner, effective June 24, 2025. Based in Boston, Donnelly comes with over 20 years of executive search experience, focusing specifically on the biopharmaceutical and life sciences industries. His extensive background includes successful placements for a wide array of clients, from emerging startups to established public companies, across various domains such as therapeutics, diagnostics, and life sciences investment. This strategic hire reflects Calibre One’s commitment to strengthening its leadership in a rapidly evolving market.
Donnelly’s previous roles include a founding Partner at a boutique executive search firm dedicated to the life sciences, where he has effectively led searches that have shaped numerous organizations. He also served as Vice President of Research at another firm, facilitating over 350 executive placements. His dual perspective as both an operator and investor positions him uniquely to understand the needs of biopharmaceutical companies seeking top-tier talent. Tom Barnes, Managing Partner at Calibre One, emphasizes Donnelly's depth of experience as a critical asset, particularly as the life sciences sector experiences significant growth and innovation.
In addition to his professional accomplishments, Donnelly holds a J.D. from Georgetown University Law Center and a B.A. in Biology from Colby College. He also actively contributes to the community as the President of the Board for Special Surfers, a nonprofit organization that provides surfing opportunities for individuals with special needs. His personal and professional values align well with Calibre One’s mission to support and advance the healthcare sector, making him a fitting addition to the firm.
In related industry news, Theravance Biopharma, Inc. recently announces that Viatris Inc. has received regulatory approval for YUPELRI® (revefenacin) in China, marking a pivotal moment for the treatment of chronic obstructive pulmonary disease (COPD). This milestone not only triggers a significant financial payment but also positions Theravance for future royalties and sales milestones, emphasizing the potential for growth in the biopharmaceutical landscape.
Additionally, Theravance is progressing its registrational study of ampreloxetine aimed at treating neurogenic orthostatic hypotension in patients with multiple system atrophy. The promising results from prior studies could lead to a New Drug Application, highlighting the ongoing innovations within the biopharmaceutical sector and the critical role of executive recruitment in navigating these advancements.